Patents by Inventor Sriram Rajagopal
Sriram Rajagopal has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 7863446Abstract: Novel heterocyclic compounds of the general formula (I), their derivatives, analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, pharmaceutically acceptable salts, pharmaceutical compositions, metabolites and prodrugs thereof are described. These compounds are useful in the treatment of immunological diseases, inflammation, pain disorder, rheumatoid arthritis; osteoporosis; multiple myeloma; uveititis; acute and chronic myelogenous leukemia; atherosclerosis; cancer; cachexia; ischemic-induced cell-damage; pancreatic beta cell destruction; osteoarthritis; rheumatoid spondylitis; gouty arthritis; inflammatory bowel disease; adult respiratory distress syndrome (ARDS); psoriasis; Crohn's disease; allergic rhinitis; ulcerative colitis; anaphylaxis; contact dermatitis; muscle degeneration; asthma; COPD; bone resorption diseases; multiple sclerosis; sepsis; septic shock; toxic shock syndrome and fever.Type: GrantFiled: February 8, 2008Date of Patent: January 4, 2011Assignee: Orchid Research Laboratories LimitedInventors: Akella Satya Surya Visweswara Srinivas, Ravikumar Tadiparthi, Ganapavarapu Veera Raghava Sharma, Sappanimuthu Thirunavukkarasu, Durairaj Peter Bhakiaraj, Virendra Kachhadia, Kilambi Narsimhan, Sathya Narayana Thara, Sriram Rajagopal, Gaddam Om Reddy, Sukunath Narayanan, Venkatesan Parameswaran, Venkatesan Janarthanam, Maruthikumar Narayanam, Sathyanarayana Gadde, Uma Ramachandran
-
Publication number: 20100329998Abstract: Described are novel heterocyclic compounds of the general formula (I), their derivatives, analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, pharmaceutically acceptable salts, pharmaceutical compositions, metabolites and prodrugs thereof. These compounds are useful in the treatment of immunological diseases, inflammation, pain disorder, rheumatoid arthritis; osteoporosis; multiple myeloma; uveititis; acute and chronic myelogenous leukemia; atherosclerosis; cancer; cachexia; ischemic-induced cell damage; pancreatic beta cell destruction; osteoarthritis; rheumatoid spondylitis; gouty arthritis; inflammatory bowel disease; ARDS; psoriasis; Crohn's disease; allergic rhinitis; ulcerative colitis; anaphylaxis; contact dermatitis; muscle degeneration; asthma; COPD; bone resorption diseases; multiple sclerosis; sepsis; septic shock; toxic shock syndrome and fever. More particularly these compounds are useful as PDE4 inhibitors and are useful for treating PDE4 mediated diseases.Type: ApplicationFiled: January 30, 2009Publication date: December 30, 2010Inventors: Visweswara Akella Satya Surya Srinivas, Ravikumar Tadiparthi, Ganapavarapu Veera Raghava Sharma, Thirunavukkarasu Sappanimuthu, Durairaj Peter Bhakiaraj, Virendra Kachhadia, Kilambi Narasimhan, Sathya Narayana Thara, Sriram Rajagopal, Om Gaddam, Nishikanth Reddy Gaddam, Sukunath Narayanan, Venkatesan Parameswaran, Venkatesan Janarthanam, Maruthikumar Narayanam, Sathyanarayana Gadde, Uma Ramachandran, Gopalan Balasubramanian, Narayanan Surendran, Shridhar Narayanan, Lolaknath Santosh Vishwakarma, Sanjeev Saxena
-
Publication number: 20100298402Abstract: Described are novel compounds of the formula (I), their derivatives, analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, intermediates, pharmaceutically acceptable salts, pharmaceutical compositions, metabolites, and prodrugs thereof. These novel compounds can inhibit pSTAT3/IL-6 and are useful as a therapeutic or ameliorating agent for diseases that are involved in cellular growth such as malignant tumors, autoimmune diseases, skin diseases, infections, inflammation, etc.Type: ApplicationFiled: November 4, 2008Publication date: November 25, 2010Applicant: ORCHID RESEARCH LABORATORIES LIMITEDInventors: Sridharan Rajagopal, Thangapazham Selvakumar, Kuppusamy Bharathimohan, Virendra Kachhadia, Sriram Rajagopal, Rajendran Praveen, Ramachandran Balaji
-
Publication number: 20100291003Abstract: Novel compounds of the general formula (I), having histone deacetylase (HDAC) inhibiting enzymatic activity, their derivatives, analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, intermediates, pharmaceutically acceptable salts, pharmaceutical compositions, metabolites and prodrugs thereof. The present invention more particularly provides novel compounds of the general formula (I). Also included is a method for treatment of cancer, psoriasis, proliferative conditions and conditions mediated by HDAC, in a mammal comprising administering an effective amount of a novel compound of formula (I).Type: ApplicationFiled: October 21, 2008Publication date: November 18, 2010Applicant: ORCHID RESEARCH LABORATORIES LIMITEDInventors: Sridharan Rajagopal, Virendra Kachhadia, Thanasekaran Ponpandian, Abdul Raheem Keeri, Karnambaram Anandhan, Sriram Rajagopal, Rajendran Praveen, Prabhu Daivasigamani
-
Publication number: 20100222379Abstract: Provided herein are novel, stilbene like compounds of the general formula (I), their derivatives, analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, metabolites, prodrugs, solvates, pharmaceutically acceptable salts and compositions thereof. These compounds can inhibit HDACs and are useful as a therapeutic or ameliorating agent for diseases that are involved in cellular growth such as WO 2009/047615 A2 malignant tumors, autoimmune diseases, skin diseases, infections, inflammation, etc.Type: ApplicationFiled: October 8, 2008Publication date: September 2, 2010Applicant: ORCHID RESEARCH LABORATORIES LIMITEDInventors: Sridharan Rajagopal, Virendra Kachhadia, Thanasekaran Ponpandian, Abdul Raheem Keeri, Umamaheswari Mani, Suresh Rathinasamy, Praveen Rajendran, Kamaraj Mani, Balaji Ramachandran, Punthalir Narayanaswamy, Sriram Rajagopal
-
Patent number: 7786142Abstract: The present invention relates to novel heterocyclic compounds of the general formula (I), as IL-6 inhibitors, their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their hydrates, their solvates, their pharmaceutically acceptable salts and compositions, their metabolites and prodrugs thereof. The present invention more particularly provides novel heterocyclic compounds of the general formula (I).Type: GrantFiled: October 12, 2006Date of Patent: August 31, 2010Assignee: Orchid Research Laboratories, Ltd.Inventors: Siripragada Mahender Rao, Akella Satya Surya Visweswara Srinvas, Shikha Rani, Gaddam Om Reddy, Sriram Rajagopal, Uma Ramachandran, Duddu Savaraiah Sharada, Rajagopalan Nirmala, Velaiah Sivasudar, Lakshmanan Manikandan, Ramachandran Balaji
-
Patent number: 7759350Abstract: The present invention relates to novel compounds of the general formula (I), their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their hydrates, their solvates, their pharmaceutically acceptable salts and compositions, their metabolites and prodrugs thereof. The present invention more particularly relates to novel pyrimidine carboxamides of the general formula (I).Type: GrantFiled: September 7, 2006Date of Patent: July 20, 2010Assignee: Orchid Research Laboratories Ltd.Inventors: Ravikumar Tadipartiii, Venkatesan Parameswaran, Rajib Barik, Gaddam Om Reddy, Pawan Aggarwal, Sappanimuthu Thirunavukkarasu, Sriram Rajagopal
-
Patent number: 7687488Abstract: Novel 2-substituted methyl penam derivatives include the formula (I), their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their solvates, their pharmaceutically acceptable salts, and pharmaceutical compositions containing them; wherein A=C or N; Het is a three- to seven-membered heterocyclic ring; R1 represents carboxylate anion, or —COOR4 where R4 represents hydrogen, carboxylic acid protecting group or a pharmaceutically acceptable salt; R2 and R3 may be same or different and independently represent hydrogen, halogen, amino, alkyl, protected amino, optionally substituted alkyl, alkenyl, alkynyl and the like; R represents substituted or unsubstituted alkyl, alkenyl, aryl, aralkyl, cycloalkyl, heterocyclyl or heterocyclylalkyl.Type: GrantFiled: July 11, 2007Date of Patent: March 30, 2010Assignee: Orchid Chemicals & Pharmaceuticals Ltd.Inventors: Senthilkumar Udayampalayam Palanisamy, Andrew Gnanaprakasam, Panchapakesan Ganapathy, Mukut Gohain, Venkatasubramanian Hariharan, Sriram Rajagopal, Maneesh Paul-Satyaseela, Shakti Singh Solanki, Sathishkumar Devarajan
-
Publication number: 20100063083Abstract: A 5(S)-(2?-hydroxyethoxy)-20(S)-camptothecin diasterisomer is described which is a better inhibitor of topoisomerase I than either the diastereoisomeric mixture 5(RS)-(2?-hydroxyethoxy)-20(S)-camptothecin, or the 5(R)-(2?-hydroxyethoxy)-20(S)-camptothecin diastereoisomer. Pharmaceutical compositions of the 5(S)-(2?-hydroxyethoxy)-20(S)-camptothecin diastereoisomer are also described as are methods of using the compound for the inhibition of topoisomerase I and for the treatment of cancer.Type: ApplicationFiled: October 12, 2009Publication date: March 11, 2010Applicant: Dr. Reddy's Laboratories LTD.Inventors: Venkateswarlu Akella, Shanavas Alikunju, Ajaya Kumar Reka, Ramesh Mullangi, Raju Sirisilla, Subrahmanyam Duvvuri, Sriram Rajagopal
-
Patent number: 7601733Abstract: A 5(S)-(2?-hydroxyethoxy)-20(S)-camptothecin diasterisomer is described which is a better inhibitor of topoisomerase I than either the diastereoisomeric mixture 5(RS)-(2?-hydroxyethoxy)-20(S)-camptothecin, or the 5(R)-(2?-hydroxyethoxy)-20(S)-camptothecin diastereoisomer. Pharmaceutical compositions of the 5(S)-(2?-hydroxyethoxy)-20(S)-camptothecin diastereoisomer are also described as are methods of using the compound for the inhibition of topoisomerase I and for the treatment of cancer.Type: GrantFiled: May 24, 2007Date of Patent: October 13, 2009Assignees: Dr. Reddy's Laboratories Limited, Dr. Reddy's Laboratories, Inc.Inventors: Venkateswarlu Akella, Shanavas Alikunju, Ajaya Kumar Reka, Ramesh Mullangi, Raju Sirisilla, Subrahmanyam Duvvuri, Sriram Rajagopal
-
Patent number: 7601732Abstract: A crystalline form of 5(S)-(2?-hydroxyethoxy)-20(S)-camptothecin diastereoisomer of 5(RS)-(2?-hydroxyethoxy)-20(S)-camptothecin is described that is characterized by having an X-ray powder diffraction pattern comprising one or more peak intensities expressed in degrees 2? that are selected from the group consisting of 7.2±0.1, 9.4±0.1, 11.02±0.1, 12.00±0.1, 14.54±0.1, 15.2±0.1, 18.92±0.1, 21.86±0.1, 22.74±0.1 and 26.42±0.1. Methods of making and using the compound are also described.Type: GrantFiled: May 24, 2007Date of Patent: October 13, 2009Assignees: Dr. Reddy's Laboratories Limited, Dr. Reddy's Laboratories, Inc.Inventors: Venkateswarlu Akella, Shanavas Alikunju, Ajaya Kumar Reka, Ramesh Mullangi, Raju Sirisilla, Subrahmanyam Duvvuri, Sriram Rajagopal
-
Publication number: 20090163521Abstract: The present invention relates to novel pyrazolopyrimidinones of the general formula (I), their derivatives, their analogs, their pharmaceutically acceptable salts and pharmaceutically acceptable compositions containing them. The present invention more particularly provides novel pyrazolopyrimidinones derivatives of the general formula (I).Type: ApplicationFiled: June 28, 2006Publication date: June 25, 2009Applicant: ORCHID RESEARCH LABORATORIES LIMITEDInventors: Ravikumar Tadiparthi, Simi Pushpan, Sriram Rajagopal, Rajib Barik
-
Publication number: 20090136431Abstract: The present invention relates to novel stilbene like compounds of the general formula (I), their derivatives, analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, pharmaceutically acceptable salts and compositions, metabolites and prodrugs thereof. The present invention more particularly provides novel stilbene like compounds of the general formula (I). Also included is a method for treatment of cancer, psoriasis, proliferative conditions and conditions mediated by HDAC, in a mammal comprising administering an effective amount of a novel compound of formula (I) as described above.Type: ApplicationFiled: November 6, 2006Publication date: May 28, 2009Applicant: ORCHID RESEARCH LABORATORIES LIMITEDInventors: Akella S.S.V. Srinivas, Urkalan K. Balan, Narayana S. Punthalir, Rama S. Velmurugan, Sriram Rajagopal, Gaddam O. Reddy, Virendra Kachhadia
-
Publication number: 20090093423Abstract: Novel 2-substituted methyl penam derivatives include the formula (I), their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their solvates, their pharmaceutically acceptable salts, and pharmaceutical compositions containing them; wherein A=C or N; Het is a three- to seven-membered heterocyclic ring; R1 represents carboxylate anion, or —COOR4 where R4 represents hydrogen, carboxylic acid protecting group or a pharmaceutically acceptable salt; R2 and R3 may be same or different and independently represent hydrogen, halogen, amino, alkyl, protected amino, optionally substituted alkyl, alkenyl, alkynyl and the like; R represents substituted or unsubstituted alkyl, alkenyl, aryl, aralkyl, cycloalkyl, heterocyclyl or heterocyclylalkyl.Type: ApplicationFiled: July 11, 2007Publication date: April 9, 2009Applicant: Orchid Chemicals and Pharmaceuticals LimitedInventors: Senthilkumar UDAYAMPALAYAMPALANISAMY, Andrew GNANAPRAKASAM, Panchapakesan GANAPATHY, Mukut GOHAIN, Venkatasubramanian HARIHARAN, Sriram RAJAGOPAL, Maneesh PAUL-SATYASEELA, Shakti SINGH SOLANKI, Sathishkumar DEVARAJAN
-
Publication number: 20080221103Abstract: Provided herein are heterocyclic compounds of the general formula (I), their derivatives, analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, pharmaceutically acceptable salts and compositions, metabolites and prodrugs thereof, wherein R1, R2, R3, R4 and R5 are as described herein. Further described herein in particular are heterocyclic compounds of the formula (I) for treating various diseases. and disorders by administering in a patient one or more TNF-?, Thromboxane synthase, 5-LOX, and PDE4 inhibitors.Type: ApplicationFiled: March 7, 2008Publication date: September 11, 2008Applicant: ORCHID RESEARCH LABORATORIES LTD.Inventors: Ganapavarapu V.R. Sharma, Gaddam O. Reddy, Sriram Rajagopal, Uma Ramachandran, Sukunath Narayanan, Nagalakshmi Pichika, Venkatesh Nemmara Viswanathan, Lavanya Andiappan, Saravanan Thirunavukkarasu
-
Publication number: 20080207606Abstract: Novel heterocyclic compounds of the general formula (I), their derivatives, analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, pharmaceutically acceptable salts, pharmaceutical compositions, metabolites and prodrugs thereof are described. These compounds are useful in the treatment of immunological diseases, inflammation, pain disorder, rheumatoid arthritis; osteoporosis; multiple myeloma; uveititis; acute and chronic myelogenous leukemia; atherosclerosis; cancer; cachexia; ischemic-induced cell-damage; pancreatic beta cell destruction; osteoarthritis; rheumatoid spondylitis; gouty arthritis; inflammatory bowel disease; adult respiratory distress syndrome (ARDS); psoriasis; Crohn's disease; allergic rhinitis; ulcerative colitis; anaphylaxis; contact dermatitis; muscle degeneration; asthma; COPD; bone resorption diseases; multiple sclerosis; sepsis; septic shock; toxic shock syndrome and fever.Type: ApplicationFiled: February 8, 2008Publication date: August 28, 2008Applicant: ORCHID RESEARCH LABORATORIES LIMITED.Inventors: Akella Satya Surya Visweswara Srinivas, Ravikumar Tadiparthi, Ganapavarapu Veera Raghava Sharma, Sappanimuthu Thirunavukkarasu, Durairaj Peter Bhakiaraj, Virendra Kachhadia, Kilambi Narsimhan, Sathya Narayana Thara, Sriram Rajagopal, Gaddam Om Reddy, Sukunath Narayanan, Venkatesan Parameswaran, Venkatesan Janarthanam, Maruthikumar Narayanam, Sathyanarayana Gadde, Uma Ramachandran
-
Publication number: 20080076791Abstract: A 5(S)-(2?-hydroxyethoxy)-20(S)-camptothecin diasterisomer is described which is a better inhibitor of topoisomerase I than either the diastereoisomeric mixture 5(RS)-(2?-hydroxyethoxy)-20(S)-camptothecin, or the 5(R)-(2?-hydroxyethoxy)-20(S)-camptothecin diastereoisomer. Pharmaceutical compositions of the 5(S)-(2?-hydroxyethoxy)-20(S)-camptothecin diastereoisomer are also described as are methods of using the compound for the inhibition of topoisomerase I and for the treatment of cancer.Type: ApplicationFiled: May 24, 2007Publication date: March 27, 2008Applicants: DR.REDDY'S LABORATORIES LIMITED, DR.REDDY'S LABRATORIES, INC.Inventors: Venkateswarlu Akella, Shanavas Alikunju, Ajaya Reka, Ramesh Mullangi, Raju Sirisilla, Subrahmanyam Duvvuri, Sriram Rajagopal
-
Publication number: 20080076790Abstract: A crystalline form of 5(S)-(2?-hydroxyethoxy)-20(S)-camptothecin diastereoisomer of 5(RS)-(2?-hydroxyethoxy)-20(S)-camptothecin is described that is characterized by having an X-ray powder diffraction pattern comprising one or more peak intensities expressed in degrees 2? that are selected from the group consisting of 7.2±0.1, 9.4±0.1, 11.02±0.1, 12.00±0.1, 14.54±0.1, 15.2±0.1, 18.92±0.1, 21.86±0.1, 22.74±0.1 and 26.42±0.1. Methods of making and using the compound are also described.Type: ApplicationFiled: May 24, 2007Publication date: March 27, 2008Applicants: DR. REDDY'S LABORATORIES LIMITED, DR. REDDY'S LABORATORIES, INC.Inventors: Venkateswarlu Akella, Shanavas Alikunju, Ajaya Reka, Ramesh Mullangi, Raju Sirisilla, Subrahmanyam Duvvuri, Sriram Rajagopal
-
Publication number: 20080015156Abstract: Novel 2-substituted methyl penam derivatives include the formula (I), their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their solvates, their pharmaceutically acceptable salts, and pharmaceutical compositions containing them; wherein A=C or N; Het is a three- to seven-membered heterocyclic ring; R1 represents carboxylate anion, or —COOR4 where R4 represents hydrogen, carboxylic acid protecting group or a pharmaceutically acceptable salt; R2 and R3 may be same or different and independently represent hydrogen, halogen, amino, alkyl, protected amino, optionally substituted alkyl, alkenyl, alkynyl and the like; R represents substituted or unsubstituted alkyl, alkenyl, aryl, aralkyl, cycloalkyl, heterocyclyl or heterocyclylalkyl.Type: ApplicationFiled: July 11, 2007Publication date: January 17, 2008Applicant: ORCHID CHEMICALS & PHARMACEUTICALS LTD.Inventors: Senthilkumar Udayampalayam Palanisamy, Andrew Gnanaprakasam, Panchapakesan Ganapathy, Mukut Gohain, Venkatasubramanian Hariharan, Sriram Rajagopal, Maneesh Paul-Satyaseela, Shakti Solanki, Sathishkumar Devarajan
-
Publication number: 20070217326Abstract: Methods and systems for transmitting a modulated frame in a block transmission system and for decoding the modulated frame when received are provided. The block transmission system is a frequency reuse system. The transmission of a frame in a block transmission system includes modulating the frame using a modulation sequence to produce a modulated frame and transmitting the modulated frame. The modulation sequence is unknown to a receiver that will receive the modulated frame, and is representative of control information.Type: ApplicationFiled: July 6, 2006Publication date: September 20, 2007Inventors: Sriram Rajagopal, Parikshith Sreebhashyam, Krishnamurthy Giridhar